Second Sight Medical Products (EYES) 16.17 $EYES
Why Second Sight Medical Products Inc. Vaulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 27, 12:41PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Al Mann's vision-restoring...
EYES: 16.17 (+4.37), MNKD: 6.52 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 11:55AM CST
EYES: 16.17 (+4.37), UNXL: 6.83 (+1.66), AIRM: 52.99 (+7.32), DGI: 33.25 (+4.80), TBIO: 1.74 (-0.47), VTAE: 11.62 (-1.66), ENOC: 13.49 (-4.87), BIOC: 3.16 (-0.34), TTI: 5.97 (+0.99), CLNE: 6.01 (+0.97), CALI: 1.17 (+0.10), RESN: 10.40 (-5.07), EGL: 36.10 (-10.35), CYCC: 1.50 (+0.41), ABTL: 12.89 (+2.51), TUBE: 13.82 (-4.12), XIN: 3.06 (+0.55), CAS: 3.22 (-1.81), TCPI: 2.74 (-3.67), WTW: 11.33 (-6.23)
Why Second Sight Medical Products, Inc. Soared Today
Daniel Sparks, The Motley Fool - Motley Fool - Tue Feb 24, 4:28PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of medical manufacturer and marketer of...
1 Comment
EYES: 16.17 (+4.37)
Second Sight Medical Products (EYES) Stock Higher Today After Success of Implants
at The Street - Tue Feb 24, 10:08AM CST
Shares of Second Sight Medical Products (EYES) are up after the company announced that its visual prosthetics have successfully been implanted in patients with retinitis pigmentosa in France.
EYES: 16.17 (+4.37)
Bioness neuromodulator cleared by FDA
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:43AM CST
BSX: 16.90 (+0.08), EYES: 16.17 (+4.37), MDT: 77.59 (-1.22), NURO: 1.65 (+0.01), STJ: 66.68 (-0.12), MNKD: 6.52 (-0.30)
Second Sight up premarket on implant progress
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:25AM CST
EYES: 16.17 (+4.37), MNKD: 6.52 (-0.30)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:16AM CST
FRO: 2.51 (-0.27), EYES: 16.17 (+4.37), BIOC: 3.16 (-0.34), AXN: 1.10 (-0.12), SPWR: 32.66 (+0.60), WIN: 7.89 (+0.12), ROSE: 17.73 (-0.64), GENE: 5.83 (-0.71), FSLR: 59.74 (+1.06), CHGG: 8.12 (+0.13), APRI: 2.20 (-0.14), CBAY: 8.45 (-0.65), CYRN: 2.80 (-0.14), CBLI: 3.38 (+0.09), TCON: 13.43 (-1.04), CAPN: 6.30 (-0.68)
Update: Second Sight Gets Renewed Approval For Treatment Of 30,000 Germans
Dallas Salazar - at Seeking Alpha - Sat Feb 07, 12:13AM CST
EYES: 16.17 (+4.37)
Why Shares of Second Sight Medical Products, Inc. Jumped Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 2:29PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Second Sight Medical Products saw its shares jump...
EYES: 16.17 (+4.37)
Second Sight Receives Highest Priority Reimbursement for Argus II in Germany
Business Wire - Tue Feb 03, 6:01AM CST
Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight" or "the Company"
, a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that InEK(1), the German national system which provides health insurance to 90% of the country's population, has renewed Status 1 for the Argus(R) II Retinal Prosthesis System under the NUB(2) innovation program.
EYES: 16.17 (+4.37)
Global Retinal Surgery Devices Market 2015-2019 with Alcon, Bausch & Lomb, Iridex & Synergetics USA Dominating
M2 - Sat Jan 31, 1:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/vfpj68/global_retinal) has announced the addition of the "Global Retinal Surgery Devices Market 2015-2019" report to their offering. The Global Retinal Surgery Devices market to grow at a CAGR of 7.32% over the period 2014-2019. The human eye is the most vital sensory organ. Ophthalmic diagnostic devices are used to identify and rectify ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. Common eye problems can be caused by an infection or can be congenital. Continuous advances in the technology of ophthalmic devices ensure efficient diagnosis and treatment. Ophthalmic devices play a major role in treating loss of vision and improving quality of life of patients. Increased use of vitrectomy machines in the treatment of retinal detachment and vitreous hemorrhage is one key trend in this market. This is because of the availability of high-quality vitrectomy machines in the market with a cutting speed of approximately 2,500 cuts/min. According to the report, increase in aging population is one of the major drivers in the market. The growing incidence of retinal disorders, such as diabetic retinopathy, AMD, macular degeneration, retinal tear, and retinal detachments among the elderly results in increased demand for retinal surgeries to prevent loss of vision. Further, the report states that the presence of substitutes for retinal surgeries is one of the major challenges that the market faces. There are several drugs available in the market for the treatment of retinal disorders. The Global Retinal Surgery Devices market is divided into four segments: Vitrectomy Packs, Retinal Lasers, Vitrectomy Machines and Others (Retinal implants, scleral buckles, light sources, light pipes, cryosurgery devices, retinal laser probes, and surgical instruments). Key Vendors - Alcon - Bausch & Lomb - Iridex - Synergetics USA Other Prominent Vendors - ASICO - Beaver-Visitec International - Biotech Visioncare - Carl Zeiss Meditec - Ellex Medical Lasers - Erbe Elektromedizin - Escalon Medical - Geuder - Insight Instruments - Lumenis - Nano Retina - Oertli Instrumente - Peregrine Surgical - Quantel Medical - Retina Implant - Rhein Medical - Second Sight Medical Products Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Incidence and Prevalence of Retinal Disorders - Regulatory Environment - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/vf...al_retinal
EYES: 16.17 (+4.37), ESMC: 1.45 (+0.06)
IPO Preview: Spark Therapeutics
IPOdesktop - Seeking Alpha - Fri Jan 30, 8:02AM CST
Based in Philadelphia, PA, Spark Therapeutics (Pending: ONCE ) scheduled an $88 million IPO on Nasdaq with a market capitalization of $352 million at a price range midpoint of $16 for Friday, Jan. 30, 2015. Price range midpoint raised to $20, no...
EYES: 16.17 (+4.37), ONCE: 57.59 (-2.66), PFE: 34.32 (-0.27)
Presbia Puts Your Reading Glasses In Your Eyeball
IPO Candy - at Seeking Alpha - Thu Jan 29, 8:02AM CST
AMSG: 60.10 (+2.13), EYES: 16.17 (+4.37), LMNS: 11.61 (+0.43), LENS: 6.98 (-0.02)
Second Sight: Initiating Bullish Below IPO Pricing Plus My Interview With CEO Robert Greenberg
Dallas Salazar - at Seeking Alpha - Tue Jan 27, 12:12PM CST
EYES: 16.17 (+4.37)
Health Care Equipment Equities Movers and Shakers - Boston Scientific, Medtronic, Zimmer Holdings, Accuray, and Second Sight Medical Products
PR Newswire - Thu Jan 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Zimmer Holdings Inc. (NYSE: ZMH), Accuray Inc. (NASDAQ: ARAY), and Second Sight Medical Products Inc. (NASDAQ: EYES). Free research report on Boston Scientific can be accessed at http://get.Investor-Edge.com/pdf/?c=Boston%20...&s=BSX. The US markets on Wednesday, January 21, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 17,554.28, up 0.22% and the NASDAQ Composite closed at 4,667.42, up 0.27%. The S&P 500 finished the session 0.47% higher at 2,032.12. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
ZMH: 120.39 (-0.94), BSX: 16.90 (+0.08), EYES: 16.17 (+4.37), MDT: 77.59 (-1.22), ARAY: 8.98 (+0.27)
Second Sight retinal device cleared in Canada
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:44AM CST
EYES: 16.17 (+4.37)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 16.17 (+4.37), ZIOP: 11.26 (-0.52), OIBR: 2.09 (-0.02), ARWR: 7.53 (-0.21), TKMR: 18.17 (-0.22), SN: 13.40 (-0.02), TIF: 88.22 (-0.48), NBG: 1.57 (-0.16), BMY: 60.92 (-0.54), LULU: 68.44 (+1.96), CPXX: 2.77 (+0.02), AGEN: 4.90 (-0.14), GDP: 4.48 (+0.24), FMI: 47.76 (-0.58), ASNA: 13.40 (+0.37), NPSP: 45.97 (+0.01), AMCO: 1.29 (-0.01), SNDK: 79.93 (+1.88)
Health Canada Approves Second Sight's Argus II Retinal Prosthesis System for Treatment of Outer Retinal Degeneration
Business Wire - Mon Jan 12, 7:00AM CST
Second Sight Medical Products, Inc. (Nasdaq: EYES) ("Second Sight" or "the Company" , a developer, manufacturer and marketer of implantable visual prosthetics to restore some functional vision to blind patients, today announced that Health Canada has approved the Argus(R) II Retinal Prosthesis System to treat individuals with severe to profound outer retinal degeneration.
EYES: 16.17 (+4.37)
Why Second Sight Medical Products Inc. Vaulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 27, 12:41PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Al Mann's vision-restoring...
EYES: 16.17 (+4.37), MNKD: 6.52 (-0.30)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 11:55AM CST
EYES: 16.17 (+4.37), UNXL: 6.83 (+1.66), AIRM: 52.99 (+7.32), DGI: 33.25 (+4.80), TBIO: 1.74 (-0.47), VTAE: 11.62 (-1.66), ENOC: 13.49 (-4.87), BIOC: 3.16 (-0.34), TTI: 5.97 (+0.99), CLNE: 6.01 (+0.97), CALI: 1.17 (+0.10), RESN: 10.40 (-5.07), EGL: 36.10 (-10.35), CYCC: 1.50 (+0.41), ABTL: 12.89 (+2.51), TUBE: 13.82 (-4.12), XIN: 3.06 (+0.55), CAS: 3.22 (-1.81), TCPI: 2.74 (-3.67), WTW: 11.33 (-6.23)
Why Second Sight Medical Products, Inc. Soared Today
Daniel Sparks, The Motley Fool - Motley Fool - Tue Feb 24, 4:28PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of medical manufacturer and marketer of...
1 Comment
EYES: 16.17 (+4.37)
Second Sight Medical Products (EYES) Stock Higher Today After Success of Implants
at The Street - Tue Feb 24, 10:08AM CST
Shares of Second Sight Medical Products (EYES) are up after the company announced that its visual prosthetics have successfully been implanted in patients with retinitis pigmentosa in France.
EYES: 16.17 (+4.37)
Bioness neuromodulator cleared by FDA
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:43AM CST
BSX: 16.90 (+0.08), EYES: 16.17 (+4.37), MDT: 77.59 (-1.22), NURO: 1.65 (+0.01), STJ: 66.68 (-0.12), MNKD: 6.52 (-0.30)
Second Sight up premarket on implant progress
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:25AM CST
EYES: 16.17 (+4.37), MNKD: 6.52 (-0.30)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:16AM CST
FRO: 2.51 (-0.27), EYES: 16.17 (+4.37), BIOC: 3.16 (-0.34), AXN: 1.10 (-0.12), SPWR: 32.66 (+0.60), WIN: 7.89 (+0.12), ROSE: 17.73 (-0.64), GENE: 5.83 (-0.71), FSLR: 59.74 (+1.06), CHGG: 8.12 (+0.13), APRI: 2.20 (-0.14), CBAY: 8.45 (-0.65), CYRN: 2.80 (-0.14), CBLI: 3.38 (+0.09), TCON: 13.43 (-1.04), CAPN: 6.30 (-0.68)
Update: Second Sight Gets Renewed Approval For Treatment Of 30,000 Germans
Dallas Salazar - at Seeking Alpha - Sat Feb 07, 12:13AM CST
EYES: 16.17 (+4.37)
Why Shares of Second Sight Medical Products, Inc. Jumped Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 2:29PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Second Sight Medical Products saw its shares jump...
EYES: 16.17 (+4.37)
Second Sight Receives Highest Priority Reimbursement for Argus II in Germany
Business Wire - Tue Feb 03, 6:01AM CST
Second Sight Medical Products, Inc. (Nasdaq:EYES) ("Second Sight" or "the Company"
, a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that InEK(1), the German national system which provides health insurance to 90% of the country's population, has renewed Status 1 for the Argus(R) II Retinal Prosthesis System under the NUB(2) innovation program. EYES: 16.17 (+4.37)
Global Retinal Surgery Devices Market 2015-2019 with Alcon, Bausch & Lomb, Iridex & Synergetics USA Dominating
M2 - Sat Jan 31, 1:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/vfpj68/global_retinal) has announced the addition of the "Global Retinal Surgery Devices Market 2015-2019" report to their offering. The Global Retinal Surgery Devices market to grow at a CAGR of 7.32% over the period 2014-2019. The human eye is the most vital sensory organ. Ophthalmic diagnostic devices are used to identify and rectify ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. Common eye problems can be caused by an infection or can be congenital. Continuous advances in the technology of ophthalmic devices ensure efficient diagnosis and treatment. Ophthalmic devices play a major role in treating loss of vision and improving quality of life of patients. Increased use of vitrectomy machines in the treatment of retinal detachment and vitreous hemorrhage is one key trend in this market. This is because of the availability of high-quality vitrectomy machines in the market with a cutting speed of approximately 2,500 cuts/min. According to the report, increase in aging population is one of the major drivers in the market. The growing incidence of retinal disorders, such as diabetic retinopathy, AMD, macular degeneration, retinal tear, and retinal detachments among the elderly results in increased demand for retinal surgeries to prevent loss of vision. Further, the report states that the presence of substitutes for retinal surgeries is one of the major challenges that the market faces. There are several drugs available in the market for the treatment of retinal disorders. The Global Retinal Surgery Devices market is divided into four segments: Vitrectomy Packs, Retinal Lasers, Vitrectomy Machines and Others (Retinal implants, scleral buckles, light sources, light pipes, cryosurgery devices, retinal laser probes, and surgical instruments). Key Vendors - Alcon - Bausch & Lomb - Iridex - Synergetics USA Other Prominent Vendors - ASICO - Beaver-Visitec International - Biotech Visioncare - Carl Zeiss Meditec - Ellex Medical Lasers - Erbe Elektromedizin - Escalon Medical - Geuder - Insight Instruments - Lumenis - Nano Retina - Oertli Instrumente - Peregrine Surgical - Quantel Medical - Retina Implant - Rhein Medical - Second Sight Medical Products Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Incidence and Prevalence of Retinal Disorders - Regulatory Environment - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/vf...al_retinal
EYES: 16.17 (+4.37), ESMC: 1.45 (+0.06)
IPO Preview: Spark Therapeutics
IPOdesktop - Seeking Alpha - Fri Jan 30, 8:02AM CST
Based in Philadelphia, PA, Spark Therapeutics (Pending: ONCE ) scheduled an $88 million IPO on Nasdaq with a market capitalization of $352 million at a price range midpoint of $16 for Friday, Jan. 30, 2015. Price range midpoint raised to $20, no...
EYES: 16.17 (+4.37), ONCE: 57.59 (-2.66), PFE: 34.32 (-0.27)
Presbia Puts Your Reading Glasses In Your Eyeball
IPO Candy - at Seeking Alpha - Thu Jan 29, 8:02AM CST
AMSG: 60.10 (+2.13), EYES: 16.17 (+4.37), LMNS: 11.61 (+0.43), LENS: 6.98 (-0.02)
Second Sight: Initiating Bullish Below IPO Pricing Plus My Interview With CEO Robert Greenberg
Dallas Salazar - at Seeking Alpha - Tue Jan 27, 12:12PM CST
EYES: 16.17 (+4.37)
Health Care Equipment Equities Movers and Shakers - Boston Scientific, Medtronic, Zimmer Holdings, Accuray, and Second Sight Medical Products
PR Newswire - Thu Jan 22, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Zimmer Holdings Inc. (NYSE: ZMH), Accuray Inc. (NASDAQ: ARAY), and Second Sight Medical Products Inc. (NASDAQ: EYES). Free research report on Boston Scientific can be accessed at http://get.Investor-Edge.com/pdf/?c=Boston%20...&s=BSX. The US markets on Wednesday, January 21, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 17,554.28, up 0.22% and the NASDAQ Composite closed at 4,667.42, up 0.27%. The S&P 500 finished the session 0.47% higher at 2,032.12. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 814.90, up 0.11%, with the index advancing 10.82% in the previous three months. Register for your complimentary reports at the links given below.
ZMH: 120.39 (-0.94), BSX: 16.90 (+0.08), EYES: 16.17 (+4.37), MDT: 77.59 (-1.22), ARAY: 8.98 (+0.27)
Second Sight retinal device cleared in Canada
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:44AM CST
EYES: 16.17 (+4.37)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 16.17 (+4.37), ZIOP: 11.26 (-0.52), OIBR: 2.09 (-0.02), ARWR: 7.53 (-0.21), TKMR: 18.17 (-0.22), SN: 13.40 (-0.02), TIF: 88.22 (-0.48), NBG: 1.57 (-0.16), BMY: 60.92 (-0.54), LULU: 68.44 (+1.96), CPXX: 2.77 (+0.02), AGEN: 4.90 (-0.14), GDP: 4.48 (+0.24), FMI: 47.76 (-0.58), ASNA: 13.40 (+0.37), NPSP: 45.97 (+0.01), AMCO: 1.29 (-0.01), SNDK: 79.93 (+1.88)
Health Canada Approves Second Sight's Argus II Retinal Prosthesis System for Treatment of Outer Retinal Degeneration
Business Wire - Mon Jan 12, 7:00AM CST
Second Sight Medical Products, Inc. (Nasdaq: EYES) ("Second Sight" or "the Company"
, a developer, manufacturer and marketer of implantable visual prosthetics to restore some functional vision to blind patients, today announced that Health Canada has approved the Argus(R) II Retinal Prosthesis System to treat individuals with severe to profound outer retinal degeneration. EYES: 16.17 (+4.37)
